PRESENTS

ASCO Direct™ Highlights
Official ASCO20 Virtual Review

2020 VIRTUAL FALL CONFERENCE
October 17, 2020 / 8:00am – 1:15pm
During this program, participants will learn about new research findings in the fields of oncology diagnosis, treatment, and care. Attendees will learn about recent advances and current evidence-based approaches to understanding and treating cancer. Attendees will acquire new knowledge and skills to improve cancer care.

Who Should Attend

This program is designed for all physicians, allied providers, and advocates including oncologists, and other physicians, as well as nurses, advanced practice registered nurses, pharmacists, genetic counselors and other practice managers.

SPEAKERS

Allison Hirschorn

Ms. Hirschorn is the Senior Coding and Reimbursement Specialist at the American Society of Clinical Oncology (ASCO). Allison completed her B.A. in Communications at the State University of New York College at Geneso. She went on to work as an Insurance Quality Analyst and served as a liaison to the Coding and Reimbursement Committee and the ICD-10 Subcommittee. She later went on to work as a Coding and Reimbursement Specialist with ASCO. She also functioned as the staff liaison to the Physician Compensation Workgroup and the Staff Coordinator for the Brown Bagging/White Bagging Workgroup. Ms. Hirschorn has presented on 2021 Evaluation and Management Changes, Basics of ICD-10, as well as Medicare Updates.

Robert Emmons, MD, FACP

Dr. Emmons is an associate professor of Medicine in the division of stem cell transplant at the UofL School of Medicine and a hematologist with UofL James Graham Brown Cancer Center. Previously, he was the medical director for the hematologic malignancy and stem cell transplant program at Ochsner Medical Center where he founded the allogeneic stem cell transplant program.

Reema A. Patel, MD,

Dr. Patel earned her medical degree from the Quillen College of Medicine at East Tennessee State University. She completed her residency in internal medicine, followed by a fellowship in medical oncology and hematology at the UK College of Medicine.

Patel is the associate program director of the Hematology & Medical Oncology Fellowship at UK and holds a faculty appointment as an assistant professor of medicine in the Division of Medical Oncology. She specializes in the treatment of bone and soft-tissue sarcomas, which are extremely rare cancers, as well as colorectal, pancreatic and hepatobiliary cancers. She provides systemic chemotherapy for both sarcomas and gastrointestinal malignancies.

Patel is part of the expert team at UK HealthCare involved in the innovative procedure known as hyperthermic intraperitoneal chemotherapy (HIPEC). She designs treatment plans for this procedure, which delivers chemotherapy directly to the abdomen during surgery.
Chandler Park, MD
Chandler Park, MD, is the President for the Kentucky Society of Clinical Oncology. Dr. Park is also a practicing cancer physician at Norton Cancer Institute and a physician member of the Molecular Tumor Board at the University of Kentucky Markey Cancer Center. He is triple-board-certified in internal medicine, hematology and oncology. Dr. Park is an American Society of Clinical Oncology (ASCO) thought expert that reviews the newest treatment and educates cancer doctors across the world at ASCO University®.

Timothy Mullett, MD, MBA, FACS
Dr. Mullett is the Medical Director with the Markey Cancer Center Network Development. He completed his medical degree at the University of Florida, College of Medicine in Gainesville and stayed to complete his Residency and Fellowship at the University of Florida Medical Center. He is a Professor of Thoracic Surgery at the University of Kentucky College of Medicine, Department of Surgery. Dr. Mullett specializes in surgical treatment for patients with lung cancer. Most recently, Dr. Mullett has been appointed as New Chair-Elect of the Commission on Cancer of the American College of Surgeons. He is a co-leader of the Kentucky LEADS Collaborative to improve lung cancer survival.

Goetz Klocker, MD, MSPH, MBA
Dr. Kloecker is a hematologist oncologist at St. Elizabeth Healthcare. He completed his medical training at the Technical University Munich in Munich, Germany. He later completed his Residency and Fellowship in Kentucky at the University of Kentucky and University of Louisville, respectively. Dr. Kloecker has over 60 publications, and his research interests include clinical trials on new chemotherapeutics and targeted agents, identification of barriers to treatment, observational studies and studies on supportive care.

Mohammed Hegazi, MD
Dr. Hegazi completed his medical training at the Mansoura University in Egypt. He later completed his Residency and Fellowship training at Jersey Shore University Medical Center and the University of Louisville School of Medicine, respectively. He is an Associate Professor with the University of Louisville School of Medicine, Department of Medicine and specializes in Medical Oncology/Hematology and BMT.
SPEAKERS

**Daniel Flora, MD**
Dr. Daniel Flora received a Doctor of Pharmacy degree from University of Cincinnati before pursuing a medical degree from Wright State Boonshoft School of Medicine. Dr. Flora completed Residency and Fellowship at University of Cincinnati. He is board certified in Internal Medicine, Hematology and Medical Oncology. Dr. Flora serves as Medical Director of the Oncology research program at St. Elizabeth Healthcare in Northern Kentucky.

**Aman Chauhan, MBBS**
Aman Chauhan, MBBS, earned his medical degree from the Kasturba Medical College in Manipal, Karnataka, India. He completed a dual residency in internal medicine and pediatrics at Louisiana State University in New Orleans. Dr. Chauhan completed a fellowship in hematology and oncology at UK with neuroendocrine tumor (NETs) training led by Lowell Anthony, MD. Additionally, Dr. Chauhan completed a Cancer Therapy Evaluation Program (CTEP) physician externship at the National Cancer institute (NCI) that focused on designing clinical trials and clinical research projects. He is an Assistant Professor of Medicine at the University of Kentucky College of Medicine.

**Jeffrey Hargis, MD**
Dr. Hargis completed his medical education at the University of Cincinnati and later completed his residency in internal medicine then his fellowship in Hematology/Oncology at the Walter Reed Army Medical Center. He is board certified in Medical Oncology and Hematology as well as Internal Medicine. Dr. Hargis subspecializes in Breast Cancer and is currently practicing with Norton Healthcare in Louisville, Kentucky.

**Barbara Logan, MS**
Ms. Logan completed her MS at Mount St. Joseph University. She later went on to work as the Clinical Research Manager at the Cincinnati Children’s Hospital Medical Center. Currently, she works as the Director of Clinical Research at St. Elizabeth. In May, she and Dr. Flora were a part of the Lancet’s article on CCC19, COVID-19 & Cancer Consortium, which works to collect and share data about cancer patients infected with the coronavirus. The registry already contains information about several thousand cancer patients with COVID-19, and details within the registry can be viewed at The Lancet (manuscript number THELANCET-D-20-09079R1). Initial results were also presented at the annual meeting of the American Society of Clinical Oncology (ASCO), which took place virtually this year.
Donald Miller, MD, PhD
Dr. Miller completed his medical training and Ph.D at Duke University School of Medicine. He completed his Residency in Boston at the Brigham and Women's Hospital and his Fellowship at the National Cancer Institute in Bethesda, MD. He is a Professor at the University of Louisville School of Medicine, Department of Medicine. Dr. Miller is the James Graham Brown Chair of Oncology and Director of the James Graham Brown Cancer Center. He also serves at the Associate Vice President of Health Affairs at the University of Louisville School of Medicine, Director for the University of Louisville M.D./Ph.D. Program and is on the Board of Directors and Founder of Advanced Cancer Therapeutics.

Roger Herzig, MD
After completing his medical degree with honors and residency at Case Western Reserve University in Cleveland, he served in the Naval Medical Corps during the Vietnam War. During this service, while working at the National Cancer Institute, he worked to develop some of the first bone marrow transplant protocols to treat leukemia and lymphoma. He then returned to Cleveland and was the founding Director of bone marrow transplant programs at University Hospital and the Cleveland Clinic, before moving to Louisville to establish the Blood & Marrow Transplant (BMT) Program at UofL Health - James Brown Cancer Center.

Lowell Anthony, MD, FACP
Lowell Anthony joined the UK Markey Cancer Center with more than two decades of experience in oncology and a special focus in gastrointestinal and neuroendocrine oncology. His clinical interests include drug development ranging from Phase I to III clinical trials. Agents targeting specific cellular signaling pathways and injectable radiolabeled compounds make up his past and current clinical investigative interests. He brings a clinical correlative component to complement the ongoing translational activities at Markey Cancer Center.

Dr. Anthony attended Vanderbilt University Medical School, where he also completed a medical residency and fellowship training in medical oncology and clinical pharmacology. He has previously been on the medical faculties at Vanderbilt University and the Louisiana State University Health Sciences Center in New Orleans.

Don Stevens, MD
Dr. Stevens is one of the four founders of Norton Cancer Institute. He was born and raised in Louisville where he received his medical education. Dr. Stevens completed his formal training in Baltimore, Maryland, at The John Hopkins Hospital. He came back to Louisville in 1989 where he has remained. Dr. Stevens is board certified in internal medicine and medical oncology.
## 2020 Virtual Conference Schedule

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00am – 8:10am</td>
<td><strong>Opening Remarks</strong>&lt;br&gt;Dr. Chandler Park, President, KYSCO</td>
</tr>
<tr>
<td>8:10am – 8:20am</td>
<td><strong>Hall of Fame Awards</strong>&lt;br&gt;Dr. Jason Chesney &amp; Dr. Elizabeth Riley</td>
</tr>
<tr>
<td>8:10am – 8:40am</td>
<td><strong>E/M Coding Now &amp; 2021</strong>&lt;br&gt;Allison Hirschorn, ASCO</td>
</tr>
<tr>
<td>8:20am – 8:45am</td>
<td><strong>Neuroendocrine Update</strong>&lt;br&gt;Aman Chauhan, MD</td>
</tr>
<tr>
<td>8:45am – 9:00am</td>
<td><strong>Fireside Chat: Oncology Medical Education and COVID-19</strong>&lt;br&gt;Phil Talamo &amp; Chandler Park, MD</td>
</tr>
<tr>
<td>9:00am – 9:30am</td>
<td><strong>Breast Cancer Update</strong>&lt;br&gt;Jeffrey Hargis, MD</td>
</tr>
<tr>
<td>9:30am – 10:00am</td>
<td><strong>Lung Cancer Update, Locally Advanced</strong>&lt;br&gt;Goetz Kloecker, MD</td>
</tr>
<tr>
<td>10:00am – 10:30am</td>
<td><strong>Gastrointestinal Update</strong>&lt;br&gt;Reema Patel, MD</td>
</tr>
<tr>
<td>10:30am – 10:40am</td>
<td><strong>Break</strong></td>
</tr>
<tr>
<td>10:40am – 11:15am</td>
<td><strong>Kentucky Cancer Update: Clinical Trials &amp; Markey Cancer Research Network</strong>&lt;br&gt;Tim Mullett, MD &amp; Lowell Anthony, MD</td>
</tr>
<tr>
<td>11:15am – 11:45am</td>
<td><strong>Myeloma &amp; Lymphoma Update</strong>&lt;br&gt;Robert Emmons, MD</td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
</tr>
<tr>
<td>---------------</td>
<td>-------------------------------------------------------------------------</td>
</tr>
<tr>
<td>11:15am – 11:45am</td>
<td><strong>CLL &amp; AML Update</strong>&lt;br&gt;  Mohammed Hegazi, MD</td>
</tr>
<tr>
<td>12:15pm-12:45pm</td>
<td><strong>COVID-19 and Cancer</strong>&lt;br&gt;  Daniel Flora, MD &amp; Barbara Logan, MS</td>
</tr>
<tr>
<td>12:30pm – 1:00pm</td>
<td><strong>Policy Update</strong>&lt;br&gt;  CMS</td>
</tr>
<tr>
<td>12:45pm -1:00pm</td>
<td><strong>Fireside Chat: Telemedicine in Oncology</strong>&lt;br&gt;  Amit Phull, MD, Peter Alperin, MD &amp; Chandler Park, MD</td>
</tr>
<tr>
<td>1:00pm –1:15pm</td>
<td><strong>Closing Remarks</strong></td>
</tr>
</tbody>
</table>

**REGISTER NOW**
Clonal evolution is a root cause of treatment resistance in multiple myeloma that may ultimately result in triple-class refractory (TCR) disease. Patients are considered TCR when they are resistant to ≥1 treatment in all 3 standard-of-care classes (proteasome inhibitors, immunomodulatory agents, and anti-CD38 monoclonal antibodies).

Peptide-drug conjugates and antibody-drug conjugates represent a strategy designed to deliver a cytotoxic agent directly into tumor cells.

Some treatments manage cancer. We're out to cure it.

Our biggest goal is to stop cancer before it can adapt and evolve. That’s why we’re developing innovative personalized therapies, and other treatments that harness the body’s natural defenses. Everything we do gets us closer to a future where cancer is a thing of the past. Learn more at www.beigene.com.
HOW DO YOU TREAT AT THE SPEED OF CANCER?

THE ANSWERS ARE IN OUR BLOOD

With Guardant360® CDx, a simple blood draw provides all the answers you need to inform fast treatment decisions for more of your patients. Get guideline-complete genomic results in only 7 days with the FIRST FDA-APPROVED comprehensive liquid biopsy for all advanced cancers. When you start with answers, you stay in control.

Order your FDA-approved test kit today
Guardant360CDx.com

For the complete intended use statement including companion diagnostic indication, please see the Guardant360 CDx Technical Information: Guardant360CDx.com/technicalinfo
Comprehensive Genomic Profiling

com•pre•hen•sive / kəˌprɛhəˈnəvı/ complete; including all elements or aspects of something

HOW DOES CARIS DEFINE COMPREHENSIVE?

22,000 DNA Genes, 62,000 mRNA Transcripts, Plus Proteins… for every patient!

Why?

22,000 DNA Genes  
62,000 mRNA Transcripts  
200,000+ Matched Patient Records  
Unique, novel signatures improve outcomes and overall survival for patients.

- Patients are our priority
- Patients of today helping patients of tomorrow
- Profile first

The Molecular Science Company. Independent and Unbiased.
Learn more at www.CarisLifeSciences.com/CGP

© 2020 Caris Life Sciences. All rights reserved. TN0584
Puma Biotechnology, Inc. is a proud sponsor of Kentucky Society of Clinical Oncology (KYSCO).

Puma is dedicated to advancing the treatment of HER2+ breast cancer and supporting patients, their families, and the breast cancer community.

For more information, visit www.pumabiotechnology.com
The leading professional medical network with over 1 Million members

www.doximity.com